GSK Touts Encouraging Data From Mid-Stage Tuberculosis Program In Drug-Susceptible Patients

GSK Touts Encouraging Data From Mid-Stage Tuberculosis Program In Drug-Susceptible Patients
  • GSK plc GSK announced positive results from a Phase 2a study demonstrating that GSK3036656, an investigational antitubercular agent, was well tolerated and showed early bactericidal activity with a low, once-daily oral dose after 14 days of treatment.
  • The trial included participants with drug-susceptible pulmonary tuberculosis (TB). 
  • Earlier this year, GSK committed to investing £1 billion over the next decade to accelerate R&D on infectious diseases, including TB, that disproportionately impact lower-income countries.
  • The anti-mycobacterial activity was demonstrated in reducing the number of viable TB cells which can multiply (colony forming units - CFU) and an increase in the time to detect bacterial growth in culture (time to positivity - TTP). 
  • In addition, PET CT imaging of the lungs showed a reduction in TB disease over 14 days in all participants taking GSK3036656 30mg.
  • The investigational antitubercular agent will be tested in Phase 2b/c studies in different drug regimens to determine the appropriate partner agents to complement its anti-TB action and the optimal regimen durations. 
  • Price Action: GSK shares are up 3.51% at $32.68 on the last check Monday.

Posted In: Briefswhy it's movingBiotechLarge CapNewsHealth CareMoversTrading IdeasGeneral